Allergy & Immunology
Latest news
92 articles · 20 / page
Paracetamol vs. Ibuprofen in Infancy: The PIPPA Tamariki Trial Finds No Differential Risk for Eczema or Bronchiolitis
The PIPPA Tamariki randomized controlled trial demonstrates that using paracetamol versus ibuprofen as needed in the first year of life does not significantly alter the risk of developing eczema or bronchiolitis by age one, challenging long
Mapping the Atopic Landscape: New Meta-Analysis Identifies Key Drivers and Critical Windows for Childhood Food Allergy
This comprehensive systematic review and meta-analysis of 190 studies involving 2.8 million participants establishes a 4.7% incidence rate for childhood food allergy and identifies early atopic conditions, microbiome disruptions, and delaye
High-Dose Prenatal Vitamin D and Childhood Atopy: Why Maternal Smoking History Matters
Recent findings from the COPSAC2010 trial and EDEN cohort suggest that high-dose prenatal vitamin D’s protective effect against atopic dermatitis is significantly enhanced in children of mothers exposed to tobacco, highlighting a potential
Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia
A groundbreaking study shows that CD19 CAR T-cell therapy can induce sustained, drug-free remission in patients with severe, multirefractory autoimmune hemolytic anemia by successfully eliminating the autoreactive B-cells that drive the dis
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inf
“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS
A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad
Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1
This case report explores the immunomodulatory effects of teplizumab in two adolescents with APS-1-associated stage 2 T1D, highlighting potential for preservation of β-cell function.
Stratifying Risk in Cow’s Milk Allergy: BAT Emerges as the Superior Biomarker for Severity and Threshold
The BAT2 study reveals that the Basophil Activation Test (BAT) is the only biomarker capable of accurately predicting reaction severity to baked milk and the sensitivity threshold for fresh milk, offering a transformative tool for clinical
FDA Approve Twice-Yearly Depemokimab for Severe Eosinophilic Asthma Management
The FDA has approved depemokimab (Exdensur), the first long-acting biologic for severe eosinophilic asthma. Requiring only two doses per year, it significantly reduces exacerbations and hospitalizations, offering a transformative shift in t
Precision Gene Correction via Prime Editing Restores NADPH Oxidase Activity in Patients with p47phox-Deficient Chronic Granulomatous Disease
A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target r
Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo
Dupilumab Surpasses Omalizumab for Type‑2 Respiratory Disease: Converging Evidence from a Head‑to‑Head RCT, Real‑World US Data, and a Target‑Trial Emulation
Three complementary studies—EVEREST (head‑to‑head RCT), the US ADVANTAGE real‑world study, and a target‑trial emulation—consistently show greater reductions in nasal polyp burden, smell loss, asthma exacerbations, and systemic steroid use w
Seborrheic Dermatitis and Epithelial Barrier Diseases: Large Cohort Studies Support a Shared Barrier‑Driven Pathogenesis
Two large US retrospective cohort studies show seborrheic dermatitis is strongly associated with a range of epithelial barrier diseases (skin, respiratory, gastrointestinal, ocular), with evidence of bidirectional risk. Findings support the
GWAS of Idiopathic Achalasia Reveals a Strong HLA Class II–Mediated Immune Aetiology and T-Cell Involvement
A first large GWAS in 4,602 idiopathic achalasia patients implicates class II HLA variation, PTPN22, TNFSF loci and a memory CD8+ T-cell subtype in disease pathogenesis, supporting an immune-mediated aetiology and offering routes for mechan
ICS–Formoterol Users Show Lower Reported Adherence but Less SABA Use: Real‑World Evidence from the MASK‑air Asthma App
Analysis of MASK‑air app data from 2015–2022 found lower self‑reported adherence to ICS+formoterol versus other ICS+LABA combinations, but paradoxically lower short‑acting β2‑agonist (SABA) use and similar symptom control in ICS+formoterol
How Milk Sugar Fuels Immune Cells to Fight Cancer: The Surprising Role of Galactose
New research reveals that galactose from dietary sources like milk reprograms liver metabolism, boosting immune T cell activity to combat tumors by preventing their exhaustion.
Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial
A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.
Unveiling Diverse Inflammatory Pathways in Residual Pediatric Asthma Exacerbations Under Mepolizumab Therapy
This study reveals multiple distinct molecular mechanisms, including epithelial and macrophage pathways, that contribute to residual asthma exacerbations in children treated with mepolizumab, highlighting the complexity of airway inflammati
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.
Browse by specialty
Open language-specific specialty feeds and department pages.